Teleflex Incorporated (TFX) Revenue by Segment & Business Profile
Vascular Access was 43.2% of Teleflex Incorporated's revenue across the 3 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TFXTeleflex IncorporatedFollow TFX — free
—
Price chart with a free account
- Market cap
- 5.8B
- P/E TTM
- —
- Dividend yield
- 1.0%
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
What the company does
Teleflex Incorporated is a medical instruments & supplies company in the healthcare sector. In its SEC filings it reports 3 business lines: Vascular Access (43%), Interventional (37%), Surgical (20%). Trailing twelve-month revenue: $2.3 billion as of 2026-06-30.
Roles we read
from the filings, not the sector label- Vascular / surgical devices
- Medical consumables / supplies
Revenue by geography
fiscal year 2025 · company segment note| Region | Revenue | Share | y/y |
|---|---|---|---|
| United States | 1.18B | 59.3% | +9.5% |
| Europe | 485M | 24.3% | +39.3% |
| Asia And Asia Pacific | 218M | 10.9% | +21.4% |
| All Other | 108M | 5.4% | +16.6% |
Teleflex Incorporated — questions
- What does Teleflex Incorporated do?
- Teleflex Incorporated is a medical instruments & supplies company in the healthcare sector. In its SEC filings it reports 3 business lines: Vascular Access (43%), Interventional (37%), Surgical (20%). Trailing twelve-month revenue: $2.3 billion as of 2026-06-30.
- How does Teleflex Incorporated make money?
- By the lines it reports in its SEC filings: Vascular Access 43.2%, Interventional 37.1%, Surgical 19.7% of revenue.
Every figure on this page comes from Teleflex Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.